PAX7 and invasive ductal breast carcinoma: The Kaplan–Meier analysis indicated that PAX7 was linked to unfavourable outcomes in the infiltrating ductal carcinoma subgroup (HR = 1.64 (1.11–2.43), p = 0.013), T3 & T4 subgroup (HR = 2.32 (1.19–4.55), p = 0.014), N1 & N2 & N3 stage subgroup (HR = 1.90 (1.25–2.89), p = 0.002), and StageIII & StageIV subgroup (HR = 1.92 (1.11–3.32), p = 0.020) (Figure 3D–G).